Avoid common mistakes on your manuscript.
1 Erratum to: BioDrugs DOI 10.1007/s40259-013-0056-z
The authors have alerted us to the following error:
Page 7, section 3.5, 3rd paragraph, lines 10–15: The following phrase which reads:
“Porkka et al. [54] showed that the incidence of pleural effusions was significantly reduced with dasatinib 100 mg four times daily compared with dasatinib 50 mg, 70 mg bid or 140 mg QD (14 % vs. 23–26 %, respectively) over a 24-month minimum follow-up.”
should read:
“Porkka et al. [54] showed that the incidence of pleural effusions was significantly reduced with dasatinib 100 mg once daily compared with dasatinib 50 mg, 70 mg bid or 140 mg QD (14 % vs. 23–26 %, respectively) over a 24-month minimum follow-up.”
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1007/s40259-013-0056-z.
Rights and permissions
About this article
Cite this article
Abruzzese, E., Breccia, M. & Latagliata, R. Erratum to: Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML). BioDrugs 28, 325 (2014). https://doi.org/10.1007/s40259-014-0093-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40259-014-0093-2